-+ 0.00%
-+ 0.00%
-+ 0.00%

IPO News | Hansatech Hong Kong Stock Exchange

Zhitongcaijing·12/03/2025 12:41:17
Listen to the news

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange disclosure on December 3, Hansi Aitai Biomedical Technology (Wuhan) Co., Ltd. (abbreviation: Hansi Aitai) submitted the Hong Kong Stock Exchange main board, and ICBC International is its sole sponsor. According to the prospectus, Hansai Tech is a biotechnology company with independent expertise and experience in structural biology, translational medicine, and clinical development. Since 2016, the company has developed a product pipeline, including a core product and nine other pipeline candidate products. According to reports, the core product HX009 is a self-developed anti-PD-1 (an immune checkpoint receptor) /SIRPα bifunctional antibody fusion protein. During the track record period and until the last practical date, the company has completed phase I clinical trials of HX009 in Australia and China.

9742641f-0254-41e3-a87a-acde9a7e4291.png